LEOBENDORF, Austria–(BUSINESS WIRE)–#aestheticmedicine–Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of itsLEOBENDORF, Austria–(BUSINESS WIRE)–#aestheticmedicine–Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its

Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF

LEOBENDORF, Austria–(BUSINESS WIRE)–#aestheticmedicine–Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1

This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice.

With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1

What makes Exprecell™ special?

  • MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1
  • Flexibility: Compatibility with Luer-Lock syringes allows flexible system integration and secure fluid transfer in a syringe of choice.
  • Safety: A closed system design limits exposure to external contaminants.
  • Usability, design, handling: Designed for a soft-single-spin process, enabling autologous PRP |Fluid-PRF preparation from whole blood with 5-minute spin time at 420xg.1*

Available Now

Exprecell™ is now available for healthcare professionals in the EU, UK & Switzerland. With this launch, Croma-Pharma further extends its commitment to providing a comprehensive and innovative portfolio to healthcare professionals.

About Croma

CROMA-PHARMA GmbH is a global player and challenger in the dynamically growing minimally invasive aesthetics market, and one of Europe’s leading manufacturers of premium-quality hyaluronic acid (HA) syringes.

Founded in 1976 by the pharmacist couple Gerhard and Karin Prinz, Croma has evolved from a family pharmacy into a globally operating Austrian company headquartered near Vienna, where it also runs its state-of-the-art, fully automated HA manufacturing plant. The company employs around 500 people, making its products available in over 80 countries worldwide. Croma offers a comprehensive and innovative aesthetics portfolio covering all key treatment categories in minimally invasive aesthetic medicine. Its range includes botulinum toxin, a broad selection of hyaluronic acid fillers, lifting threads (PDO threads), Polynucleotide injectables and HA skin booster. With this full-face approach, Croma provides aesthetic professionals and their patients with safe, effective, and reliable solutions from a single trusted source. Building on its heritage in ophthalmology and orthopaedics, Croma transferred its pharmaceutical expertise and stringent quality standards to aesthetic applications. The company exceeded over 110 million syringes produced in 2025, reinforcing its position as one of Europe’s foremost HA manufacturers.

References:

*For full instructions, please refer to the IFU.

1 Data on file

The healthcare professional confirms having informed the patient of a likely risk of the medical device in line with its intended use. For risks and adverse events associated with the use of the medical device consult the instructions of use. CE 2797

EPR112025

Contacts

Press contact:
CROMA-PHARMA GmbH

Victoria Szafraniec

Global Digital Media & PR Manager

Cromazeile 2

A-2100 Leobendorf

Phone: +43 676 846 868 494

Mail: victoria.szafraniec@croma.at
Web: www.cromapharma.com

Market Opportunity
Instadapp Logo
Instadapp Price(FLUID)
$2.5801
$2.5801$2.5801
-6.15%
USD
Instadapp (FLUID) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

SEC Staff Clarifies Custody Rules for Tokenized Stocks and Bonds

SEC Staff Clarifies Custody Rules for Tokenized Stocks and Bonds

The post SEC Staff Clarifies Custody Rules for Tokenized Stocks and Bonds appeared on BitcoinEthereumNews.com. The US Securities and Exchange Commission’s Trading
Share
BitcoinEthereumNews2025/12/19 08:51
Breaking: CME Group Unveils Solana and XRP Options

Breaking: CME Group Unveils Solana and XRP Options

CME Group launches Solana and XRP options, expanding crypto offerings. SEC delays Solana and XRP ETF approvals, market awaits clarity. Strong institutional demand drives CME’s launch of crypto options contracts. In a bold move to broaden its cryptocurrency offerings, CME Group has officially launched options on Solana (SOL) and XRP futures. Available since October 13, 2025, these options will allow traders to hedge and manage exposure to two of the most widely traded digital assets in the market. The new contracts come in both full-size and micro-size formats, with expiration options available daily, monthly, and quarterly, providing flexibility for a diverse range of market participants. This expansion aligns with the rising demand for innovative products in the crypto space. Giovanni Vicioso, CME Group’s Global Head of Cryptocurrency Products, noted that the new options offer increased flexibility for traders, from institutions to active individual investors. The growing liquidity in Solana and XRP futures has made the introduction of these options a timely move to meet the needs of an expanding market. Also Read: Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple! Rapid Growth in Solana and XRP Futures Trading CME Group’s decision to roll out options on Solana and XRP futures follows the substantial growth in these futures products. Since the launch of Solana futures in March 2025, more than 540,000 contracts, totaling $22.3 billion in notional value, have been traded. In August 2025, Solana futures set new records, with an average daily volume (ADV) of 9,000 contracts valued at $437.4 million. The average daily open interest (ADOI) hit 12,500 contracts, worth $895 million. Similarly, XRP futures, which launched in May 2025, have seen significant adoption, with over 370,000 contracts traded, totaling $16.2 billion. XRP futures also set records in August 2025, with an ADV of 6,600 contracts valued at $385 million and a record ADOI of 9,300 contracts, worth $942 million. Institutional Demand for Advanced Hedging Tools CME Group’s expansion into options is a direct response to growing institutional interest in sophisticated cryptocurrency products. Roman Makarov from Cumberland Options Trading at DRW highlighted the market demand for more varied crypto products, enabling more advanced risk management strategies. Joshua Lim from FalconX also noted that the new options products meet the increasing need for institutional hedging tools for assets like Solana and XRP, further cementing their role in the digital asset space. The launch of options on Solana and XRP futures marks another step toward the maturation of the cryptocurrency market, providing a broader range of tools for managing digital asset exposure. SEC’s Delay on Solana and XRP ETF Approvals While CME Group expands its offerings, the broader market is also watching the progress of Solana and XRP exchange-traded funds (ETFs). The U.S. Securities and Exchange Commission (SEC) has delayed its decisions on multiple crypto-related ETF filings, including those for Solana and XRP. Despite the delay, analysts anticipate approval may be on the horizon. This week, REX Shares and Osprey Funds are expected to launch an XRP ETF that will hold XRP directly and allocate at least 40% of its assets to other XRP-related ETFs. Despite the delays, some analysts believe that approval could come soon, fueling further interest in these assets. The delay by the SEC has left many crypto investors awaiting clarity, but approval of these ETFs could fuel further momentum in the Solana and XRP futures markets. Also Read: Tether CEO Breaks Silence on $117,000 Bitcoin Price – Market Reacts! The post Breaking: CME Group Unveils Solana and XRP Options appeared first on 36Crypto.
Share
Coinstats2025/09/18 02:35
US Lawmakers May Limit De Minimis Tax Exemptions to Stablecoins, Excluding Bitcoin

US Lawmakers May Limit De Minimis Tax Exemptions to Stablecoins, Excluding Bitcoin

The post US Lawmakers May Limit De Minimis Tax Exemptions to Stablecoins, Excluding Bitcoin appeared on BitcoinEthereumNews.com. US lawmakers are considering de
Share
BitcoinEthereumNews2025/12/19 09:28